We are live on ! Find out more
ENZN

ENZON PHARMACEUTICALS INC
ENZN

Delisted

ENZN was delisted on the 19th of May, 2016.

Back to rankings

40 hedge funds and large institutions have $8.07M invested in ENZON PHARMACEUTICALS INC in 2016 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 8 increasing their positions, 10 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

18% less funds holding

Funds holding: 49 → 40 (-9)

20% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 10

37% less capital invested

Capital invested by funds: $12.7M → $8.07M (-$4.64M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 9

Holders
40
Holders Change
-9
Holders Change %
-18.37%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
8
Reduced
10
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$24.5K
2
UBS Group
UBS Group
Switzerland
+$14.2K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$12.6K
4
OSAM
O'Shaughnessy Asset Management
Connecticut
+$4.65K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$2.13K

Top Sellers

Rank Fund Capital Flow
1
SCP
Seizert Capital Partners
Michigan
-$283K
2
Renaissance Technologies
Renaissance Technologies
New York
-$175K
3
KBC Group
KBC Group
Belgium
-$117K
4
AG
Algert Global
California
-$85K
5
Morgan Stanley
Morgan Stanley
New York
-$39.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
IC
1
Icahn Carl
Florida
$2.77M – – –
Renaissance Technologies
2
Renaissance Technologies
New York
$1.48M -$175K -358,000 -10%
BIT
3
BlackRock Institutional Trust
California
$1.33M -$16.1K -32,915 -1%
Vanguard Group
4
Vanguard Group
Pennsylvania
$706K +$12.6K +25,720 +2%
UBS Group
5
UBS Group
Switzerland
$340K +$14.2K +29,046 +4%
BA
6
BlackRock Advisors
Delaware
$317K -$9.66K -19,796 -3%
Connor, Clark & Lunn Investment Management (CC&L)
7
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$269K – – –
Jacobs Levy Equity Management
8
Jacobs Levy Equity Management
New Jersey
$246K +$24.5K +50,157 +11%
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$119K – – –
BCM
10
Bridgeway Capital Management
Texas
$72K – – –
Arrowstreet Capital
11
Arrowstreet Capital
Massachusetts
$54K – – –
Acadian Asset Management
12
Acadian Asset Management
Massachusetts
$54K +$2.13K +4,368 +4%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$49K -$4.39K -8,993 -8%
BIM
14
Bogle Investment Management
Massachusetts
$48K -$2.32K -4,745 -4%
CL
15
CSS LLC
Illinois
$44K -$1.95K -4,000 -4%
Northern Trust
16
Northern Trust
Illinois
$38K – – –
Tudor Investment Corp
17
Tudor Investment Corp
Connecticut
$23K – – –
CWM
18
Concert Wealth Management
California
$21K – +1 +0%
Goldman Sachs
19
Goldman Sachs
New York
$14K -$37K -75,789 -72%
State Street
20
State Street
Massachusetts
$13K – – –
SIM
21
Spark Investment Management
New York
$11K -$15.8K -32,400 -56%
Charles Schwab
22
Charles Schwab
California
$11K – – –
OSAM
23
O'Shaughnessy Asset Management
Connecticut
$10K +$4.65K +9,535 +76%
Two Sigma Advisers
24
Two Sigma Advisers
New York
$7K – – –
MCM
25
Monarch Capital Management
Indiana
$5K – – –
1
2

ENZN Hedge Fund Activity: Q1 2016 in Review

40 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ENZON PHARMACEUTICALS INC (ENZN) for Q1 2016, worth a combined $8.07M — down 37% from $12.7M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of ENZN and 0 opened new positions — a net loss of 9 holders — while 10 trimmed existing stakes and 8 added.

The largest buyer was Jacobs Levy Equity Management, adding an estimated $24.5K. The largest seller was Seizert Capital Partners, exiting entirely with an estimated $283K sold.

  • 40 institutional investors held ENZON PHARMACEUTICALS INC (ENZN) as of Q1 2016, down from 49 in Q4 2015.
  • Funds reported $8.07M of ENZON PHARMACEUTICALS INC stock for Q1 2016, down 37% quarter-over-quarter.
  • 0 funds opened new ENZON PHARMACEUTICALS INC positions in Q1 2016 and 9 closed out, a net change of -9 holders.
  • The largest ENZON PHARMACEUTICALS INC buyer in Q1 2016 was Jacobs Levy Equity Management, an estimated $24.5K added.
  • The largest ENZON PHARMACEUTICALS INC seller in Q1 2016 was Seizert Capital Partners, an estimated $283K sold.

Based on aggregated 13F filings for Q1 2016.